Pathstone Holdings
VTVT icon

Pathstone Holdings’s vTv Therapeutics VTVT Stock Holding History

Pathstone Holdings’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Hold
6,073
– – ﹤0.01% 2183
2026
Q1 		$241K Hold
6,073
– – ﹤0.01% 2043
2025
Q4 		$243K Buy
+6,073
New +$169K ﹤0.01% 2042

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's VTVT Position: Q2 2026 in Review

Pathstone Holdings held its vTv Therapeutics (VTVT) position steady in Q2 2026 at 6,073 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #2183.

Pathstone Holdings first reported a position in VTVT in Q4 2025 and has held it in 3 quarters since. The position peaked at $243K in Q4 2025. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Pathstone Holdings held 6,073 shares of vTv Therapeutics worth $229K as of Q2 2026.
  • Pathstone Holdings left its vTv Therapeutics share count unchanged in Q2 2026.
  • vTv Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2183 holding.
  • Pathstone Holdings first reported a position in vTv Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pathstone Holdings's vTv Therapeutics position peaked at $243K in Q4 2025.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.